Skip to Main content Skip to Navigation
Journal articles

Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1

Maureen Martin 1 Vivek Naranbhai 2, 3 Patrick Shea 4 Ying Qi 1 Veron Ramsuran 1, 3, 5 Nicolas Vince 1, 6, 7, 8, * Xiaojiang Gao 1 Rasmi Thomas 9, 10 Zabrina Brumme 11, 12 Jonathan Carlson 13 Steven Wolinsky 14 James Goedert 15 Bruce D. Walker 2 Florencia Segal 16 Steven G Deeks 17 David Haas 18 Stephen Migueles 19 Mark Connors 19 Nelson Michael 9, 10 Jacques Fellay 20 Emma Gostick 21, 22 Sian Llewellyn-Lacey 21, 22 David A. Price 21, 23 Bernard Lafont 24 Phillip Pymm 25 Philippa Saunders 26 Jacqueline Widjaja 26 Shu Wong 26 Julian Vivian 25 Jamie Rossjohn 21, 22, 25 Andrew Brooks 26 Mary Carrington 1, 2
* Corresponding author
1 Leidos Biomedical Research Inc. - Cancer and Inflammation Program [Frederick, MD, USA]
2 Ragon Institute of MGH, MIT and Harvard
3 CAPRISA - Centre for the AIDS Programme of Research [Durban, South Africa]
4 Institute for Genomic Medicine [New York, NY, USA]
5 KRISP - KwaZulu-Natal Research Innovation and Sequencing Platform [Durban, South Africa]
6 ITUN - Institut de transplantation urologie-néphrologie
7 CHU Nantes - Centre hospitalier universitaire de Nantes
8 Team 5 - U1064 Inserm - CRTI - Translational ImmunoGenetic in AutoImmunity and Transplantation
U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie
9 US Military HIV Research Program [Silver Spring, MD, USA]
10 HJM - Henry M. Jackson Foundation for the Advancement of Military Medicine
11 Faculty of Health Sciences [Burnaby, BC, Canada]
12 British Columbia Centre for Excellence in HIV/AIDS [Vancouver, BC, Canada]
13 Microsoft Research [Redmond]
14 Division of Infectious Diseases [Chicago, IL, USA]
15 Infections and Immunoepidemiology Branch [Bethesda, MD, USA]
16 BWH - Brigham & Women’s Hospital [Boston]
17 San Francisco General Hospital Medical Center [San Francisco, CA, USA]
18 Vanderbilt University School of Medicine [Nashville]
19 Laboratory of Immunoregulation [Bethesda, MD, USA]
20 School of Life Sciences [Lausanne]
21 School of Medicine [Cardiff]
22 Non-Human Primate Immunogenetics and Cellular Immunology Unit [Bethesda, MD, USA]
23 Vaccine Research Center - Human Immunology Section [Bethesda, MD, USA]
24 Office of the Scientific Director - Viral Immunology Section [Bethesda, MD, USA]
25 Department of Biochemistry and Molecular Biology - Infection and Immunity Program [Victoria, Australia]
26 Department of Microbiology and Immunology [Victoria, Australia]
Abstract : HLA-B*57 control of HIV involves enhanced CD8+ T cell responses against infected cells, but extensive heterogeneity exists in the level of HIV control among B*57+ individuals. Using whole-genome sequencing of untreated B*57+ HIV-1-infected controllers and noncontrollers, we identified a single variant (rs643347A/G) encoding an isoleucine-to-valine substitution at position 47 (I47V) of the inhibitory killer cell immunoglobulin-like receptor KIR3DL1 as the only significant modifier of B*57 protection. The association was replicated in an independent cohort and across multiple outcomes. The modifying effect of I47V was confined to B*57:01 and was not observed for the closely related B*57:03. Positions 2, 47, and 54 tracked one another nearly perfectly, and 2 KIR3DL1 allotypes differing only at these 3 positions showed significant differences in binding B*57:01 tetramers, whereas the protective allotype showed lower binding. Thus, variation in an immune NK cell receptor that binds B*57:01 modifies its protection. These data highlight the exquisite specificity of KIR-HLA interactions in human health and disease.
Document type :
Journal articles
Complete list of metadata

Cited literature [59 references]  Display  Hide  Download
https://www.hal.inserm.fr/inserm-02156536
Contributor : Sylvie Le Bihan Connect in order to contact the contributor
Submitted on : Friday, June 14, 2019 - 2:21:25 PM
Last modification on : Friday, December 18, 2020 - 6:46:05 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

  • HAL Id : inserm-02156536, version 1

Collections

INSERM | UNIV-NANTES | CRTI

Citation

Maureen Martin, Vivek Naranbhai, Patrick Shea, Ying Qi, Veron Ramsuran, et al.. Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. Journal of Clinical Investigation, American Society for Clinical Investigation, 2018, 128 (5). ⟨inserm-02156536⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

144